GSK presented groundbreaking data from its oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress. These presentations highlight GSK’s commitment to enhancing treatment outcomes for patients battling blood cancers, gynecologic cancers, and other solid tumors through innovative therapeutic strategies.
Advancements in Multiple Myeloma Treatment
At ASCO and EHA, GSK showcased significant updates from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) program. Key findings include improved progression-free survival from the DREAMM-8 study and the first safety and efficacy data for the unconjugated monoclonal antibody belantamab in the DREAMM-20 trial. Additionally, new analyses from DREAMM-7 and DREAMM-8 emphasized the management of ocular side effects, enhancing the drug’s safety profile for relapsed or refractory multiple myeloma patients.
Innovative Therapies for Gynecologic Cancers
GSK also presented new data on its treatments for advanced ovarian and endometrial cancers. The phase III FIRST-ENGOT-OV44 trial revealed the benefits of adding dostarlimab to platinum-based chemotherapy, followed by niraparib maintenance. Results from the PRIMA trial highlighted the impact of disease progression on patients’ quality of life, while the RUBY trial provided insights into the effects of dostarlimab on health-related outcomes in endometrial cancer patients.
• Early intervention with momelotinib may significantly improve survival rates in myelofibrosis patients.
• Belantamab mafodotin shows promise in redefining treatment protocols for multiple myeloma.
• Combining immunotherapies with traditional chemotherapy enhances treatment efficacy in gynecologic cancers.
GSK’s robust presentation at these conferences underscores the company’s dedication to advancing cancer treatment through cutting-edge research and clinical trials. The data presented not only demonstrate the efficacy of GSK’s current therapies but also pave the way for future innovations in oncology.
GSK continues to lead the charge in oncology by focusing on patient-centered research and the development of therapies with manageable side effects. The company’s strategic investments in multiple myeloma, myelofibrosis, and gynecologic cancers reflect a comprehensive approach to tackling some of the most challenging forms of cancer, ultimately aiming to improve patient outcomes and quality of life.
GSK’s ongoing efforts in clinical research and development are set to make a significant impact on cancer treatment protocols globally. By prioritizing both efficacy and patient well-being, GSK positions itself as a pivotal player in the fight against cancer, offering hope to millions of patients worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
